Long-term safety and effectiveness of lurasidone in schizophrenia: A 22-month, open-label extension study

CNS Spectrums

Volumn 21, Issue 5, 2016, Pages 393-402

  Correll, Christoph U ^a   Cucchiaro, Josephine ^b   Silva, Robert ^b   Hsu, Jay ^b   Pikalov, Andrei ^b   Loebel, Antony ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Atypical antipsychotic; lurasidone; maintenance treatment; safety; schizophrenia

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; PLACEBO; PROLACTIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; LIPID BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; AKATHISIA, DRUG-INDUCED; BLOOD; CHEMICALLY INDUCED; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYNDROME; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; DISORDERS OF EXCESSIVE SOMNOLENCE; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LONGITUDINAL STUDIES; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84964078725     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852915000917     Document Type: Article

References (37)

1. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-Treatments meta-Analysis. Lancet. 2013; 382(9896): 951-962
2. Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011; 25(5): 567-620
3. Glick ID, Correll CU, Altamura CA, et al. Mid-Term and long-Term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized, clinical approach. J Clin Psychiatry. 2011; 72(12): 1616-1627
4. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011; 17(2): 97-107
5. De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2): 114-126
6. Mitchell AJ, Vancampfort D, Sweers K, vanWinkel R, YuW, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-A systematic review and meta-Analysis. Schizophr Bull. 2013; 39(2): 306-318
7. Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT Cardiovascular and cerebrovascular risk factors and events associated with secondgeneration antipsychotic compared to antidepressant use in a nonelderly adult sample: results from a claims-based inception cohort study.World Psychiatry. 2015; 14(1): 56-63
8. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171-181
9. NakamuraM, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829-836
10. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo and olanzapine-controlled study. Am J Psychiatry. 2011; 168(9): 957-967
11. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65(2): 189-210
12. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013; 225(3): 519-530
13. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- And activecontrolled trial. Schizophr Res. 2013; 145(1-3): 101-109
14. Sunovion Pharmaceuticals. Latuda (lurasidone HCl tablets). Prescribing Information. http: //www.latuda.com/LatudaPrescribingInformation.pdf. Accessed March 4, 2015
15. Sunovion Pharmaceuticals. Lurasidone Summary of Product Characteristics. March 21 2014. http: //www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002713/WC500164683.pdf. Accessed February 15, 2016
16. De Hert M, Yu WP, Detraux J, Van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-Analysis. CNS Drugs. 2012; 26(9): 733-759
17. Citrome L, Cucchiaro J, Sarma K, et al. Long-Term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165-176
18. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507-515
19. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1): 95-102
20. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; 162(3): 441-449
21. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013; 47(5): 670-677
22. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212: 11-19
23. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154(5): 672-676
24. Guy W, ed. CDEU Assessment Manual for Psychopharmacology Publication ADM 76-338 Washington, DC: US Department of Health, Education, and Welfare; 1976: 534-537
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276
26. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382-389
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223
28. Buckley PF. Maintenance treatment for schizophrenia with quetiapine. Hum Psychopharmacol. 2004; 19(2): 121-124
29. Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, Loebel A. Long-Term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165-176
30. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence fromthe CATIE study. Schizophr Res. 2011; 133(1-3): 42-46
31. Ösby U, Correia N, Brandt L, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000; 321(7259): 483-484
32. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005; 150(6): 1115-1121
33. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007; 64(10): 1123-1131
34. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010; 196(2): 116-121
35. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009; 113(1): 1-11
36. Meyer JM. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010; 4: 23-42
37. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011; 45(10): 830-837